Close this search box.


Top Strategies for Ensuring the Success of Your New Drug Application (NDA)

Understanding What is New Drug Application (NDA) and Its Importance

You’ve spent years dreaming of bringing a revolutionary drug to the market. You’re now ready to try making that dream a reality with a new drug application (NDA), and you’re in excellent company. Research shows nearly 60 novel drugs were awaiting approval by the Food and Drug Administration (FDA) in the fall of 2023 for the period ranging from the spring of 2023 to early 2024. These drugs were intended to treat cancers, rare diseases (e.g., the blood disorder called sickle cell anemia), and autoimmune conditions (e.g., the immune system disease lupus). NDAs are essential in today’s pharmaceutical industry because they’re how people propose to FDA officials that new drugs be approved for marketing and sale nationwide. An NDA allows you to tell a drug’s complete story. It includes its contents, manufacturing process, packaging, and trial results. Your goal with an NDA is to show that your new drug is effective and safe. The NDA process’s nonclinical side is critical. It involves several evaluations and studies before testing a human.

The FDA reviews the NDA to determine whether the drug is safe and effective for its intended use and whether its benefits outweigh its risks. The approval of an NDA is a crucial step in the drug development process, as it allows the drug to be marketed and sold in the United States. The NDA process is complex and can take several years to complete. It involves extensive testing and clinical trials to ensure the safety and efficacy of the drug. The FDA also thoroughly reviews the manufacturing process and labeling to ensure that the drug is produced and marketed safely and responsibly. In summary, the NDA is an essential component of the drug development process, as it provides the FDA with the necessary information to make an informed decision about the safety and efficacy of a new drug. Without the approval of an NDA, a new drug cannot be marketed or sold in the United States. It’s never too early to start planning for your NDA. Let’s explore how to ensure your NDA is met with success.

Nonclinical Component of an NDA

Nonclinical studies in an NDA are also called preclinical studies. They help drug makers identify promising medication candidates and assess their safety for initial human testing. Preclinical animal study data play a significant role in NDA submission by determining the following details about your new drug:

  • Potential toxicity (its potential to cause side effects like rashes)
  • Pharmacodynamics (how the drug works in the body)
  • Pharmacokinetics (what patients’ bodies do to the drug)

Animal study data also help you establish the initial human trial drug dosing regimen. You can generate these data by observing and recording the effects of various doses on the animal subjects of your studies. The relationship between nonclinical data and drug efficacy is vital, too. Your preclinical data may indicate your drug’s therapeutic potential early by highlighting how it affects the body. Remember that animal models don’t perfectly reproduce human responses. They’re still helpful for predicting possible outcomes in humans, however.

Navigating CDISC SEND Standards for NDAs

Understanding the clinical data interchange standards consortium (CDISC) standard for exchange of nonclinical data, or SEND, is critical for success with your NDA. Let’s examine what SEND is and why it’s essential.

Importance of SEND

SEND outlines the proper format for presenting and collecting nonclinical data to the FDA. Failure to follow this format will result in the denial of your application. This standard is required since it helps ensure that your nonclinical data are accessible for regulatory authorities to review. A consistent format can also help you maintain transparency during the medication approval. Another reason why SEND is essential is it streamlines the process of exchanging nonclinical data among various software systems. This promotes data sharing and collaboration.

The importance of SEND lies in its ability to facilitate the review and evaluation of nonclinical data by regulatory authorities, which is a critical step in the drug development process. By adhering to the SEND standard, sponsors can ensure that their nonclinical data is submitted in a format that is easily accessible and understandable by regulatory authorities, which can help expedite the review process and ultimately lead to faster drug approvals. Additionally, SEND can help improve the quality and consistency of nonclinical data, leading to more accurate and reliable results. Overall, using SEND is essential to drug development and can help ensure that new drugs are safe and effective for patients.

SEND Compliance and Quality

Adhering to SEND helps ensure your data’s integrity and quality. Complying with SEND enhances the quality of your nonclinical data submission because using standardized data structures and terms helps decrease errors and improve the accuracy of your submitted data. SEND compliance and quality are crucial aspects of drug development and regulatory submissions. Compliance with SEND standards ensures that the data presented is consistent, accurate, and can be easily reviewed by regulatory agencies. Quality control measures are also essential to ensure the data is reliable and meets the required standards. Xybion offers solutions to help organizations achieve SEND compliance and maintain data quality throughout drug development.

SEND Challenges

SEND (standard for exchange of nonclinical data) is critical to drug development and regulatory submissions. However, it can also present challenges for organizations. Some common SEND challenges include:

Data standardization: Ensuring that data is standardized and consistent across different studies can be challenging, especially when dealing with legacy data.

Data quality: Ensuring accurate, complete, and reliable data is crucial for regulatory compliance. However, data quality can be compromised due to data collection, processing, or analysis errors.

Data management: Managing large volumes of data can be daunting, especially when dealing with multiple studies and data sources.

Compliance: Ensuring compliance with regulatory requirements and guidelines can be challenging, especially when dealing with evolving standards and guidelines.

Integration: Integrating SEND data with other systems and processes can be challenging, especially when dealing with legacy systems and data sources. Organizations can leverage technology solutions such as Xybion SEND Intelligence Services to overcome these challenges.

Effective Strategies for NDA Submission

Several tips can help you successfully submit your NDA to the FDA, including engaging in comprehensive planning. Creating a detailed plan before you conduct your preclinical studies can help you align nonclinical studies with NDA requirements. Let’s review other best practices for NDA submission.

Data Integrity

Ensuring the completeness and accuracy of your nonclinical data is also a critical part of the NDA process. You can achieve data integrity by providing all data are traceable to those who produced them. Correctly identify the parties performing the data-generating tasks and when these tasks were completed. Maintain your data in an understandable and readable format, electronically or on paper. Record the data immediately to avoid forgetting details when recording them later. Not transcribing data several times is another way to protect your data’s integrity since this can help prevent you from introducing errors.

Advanced Preparation

Understanding the FDA’s timelines and expectations can help ensure a successful NDA submission process. The FDA must decide within 60 days whether it will file a submitted NDA for review. Suppose officials accept your NDA for filing. You’ll receive an application review timeline in a 74-day FDA letter. Administration reviewers will ultimately approve your NDA or send you a letter explaining issues needing addressing.

Technology Use

Leveraging tools and software for efficient data management is another crucial step in NDA submission. Data management solutions like Oracle and Microsoft Access are other software options that can help with data checking.

SEND-Managed Services

Consider using Xybion’s SEND Intelligence Services to streamline the nonclinical component of your NDA. Xybion can create a custom solution for standardizing your preclinical study data’s format. It can make the NDA regulatory review step more efficient for you. SEND-managed services with Xybion SEND Intelligence Services is a comprehensive solution that helps pharmaceutical companies and contract research organizations (CROs) manage their SEND data more efficiently and effectively. With Xybion SEND Intelligence Services, companies can streamline their SEND data management processes, reduce errors, and ensure compliance with regulatory requirements.

Streamline NDA Submission with Xybion SEND Intelligence Services

Nonclinical data management in a new drug application (NDA) is important because data from animal studies can help you assess your new drug’s safety for human testing. It can also help determine your drug’s therapeutic potential. Adhering to CDISC SEND requirements is an essential part of the NDA process. It will help ensure your data are presented in a standardized, accurate format for quick review by the FDA.

Utilizing Xybion’s SEND Intelligence Services can help you achieve NDA success on the nonclinical study side. Xybion SEND Intelligence Services provides a range of managed services, including SEND data conversion, SEND data validation, and SEND data submission. The solution is designed to help companies manage their SEND data from start to finish, ensuring that the data is accurate, complete, and compliant with regulatory requirements. One of the critical benefits of Xybion SEND Intelligence Services is that it is a fully managed solution. It means that Xybion’s team of experts will handle all aspects of SEND data management, from data conversion to submission. It allows companies to focus on their core business activities while Xybion takes care of the SEND data management process. Our team of experts is dedicated to providing you with the highest quality service and support to ensure that your submission complies with all regulatory requirements. During your free consultation, we will work with you to understand your specific needs and requirements and provide a customized solution that meets your needs. Our team will guide you through the entire process, from data collection and analysis to submission and post-submission support. With Xybion SEND Intelligence Services, you can be confident that your NDA submission will be accurate, complete, and compliant with all regulatory requirements. Our services are designed to help you save time and reduce costs while ensuring that your submission is of the highest quality. Increase your NDA’s chances of getting approved by booking a consultation with our SEND experts today!


Ready to learn more? Talk to our SEND experts!